We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nabilone & Marijuana Addiction

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01025700
First Posted: December 3, 2009
Last Update Posted: February 17, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of British Columbia
  Purpose
Safety of Nabilone in reducing marijuana craving

Condition Intervention Phase
Marijuana Smoking Drug: Cesemat Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Safety and tolerability to Nabilone

Secondary Outcome Measures:
  • Marijuana craving questionnaire

Estimated Enrollment: 35
Study Start Date: June 2009
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cesemat Drug: Cesemat
1 mg capsule per day for 21 days
Other Name: Nabilone
No Intervention: Placebo

Detailed Description:
Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 19 years or older
  • History of marijuana use
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025700


Locations
Canada, British Columbia
Vancouver General Hospital - Psychiatry Outpatient
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Shaohua Lu, MD University of British Columbia
  More Information

Responsible Party: Shaohua Lu, MD, University of British Columbia
ClinicalTrials.gov Identifier: NCT01025700     History of Changes
Other Study ID Numbers: H08-01999
First Submitted: December 2, 2009
First Posted: December 3, 2009
Last Update Posted: February 17, 2011
Last Verified: February 2011

Keywords provided by University of British Columbia:
Efficacy
Marijuana
Reduction
Craving

Additional relevant MeSH terms:
Marijuana Abuse
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nabilone
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs